Drugs / AMG 596
last change Aug 2021 re-read 2 minutes ago

AMG 596

Developed for
malignant glioma
Investigated by
Amgen

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03296696 Apr 2018 → Jul 2021 malignant glioma Amgen Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AMG 596 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03296696